<style face="normal" font="default" size="100%">Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with CancerPurpose:Experimental Design:Results:Conclusions:</style>

Drupal-Biblio